Poolbeg Pharma plc
Poolbeg Pharma plc is a clinical-stage, pre-revenue UK biopharmaceutical company focused on transforming cancer immunotherapy. Its lead asset POLB 001, an orally delivered p38 MAPK inhibitor, is being developed as a preventative therapy for cancer immunotherapy-induced Cytokine Release Syndrome (CRS). The company is also developing an oral encapsulated GLP-1 programme for obesity with partner AnaBio, and is exploring AI-led drug discovery collaborations.
No price history · 5 reported years, FY2021–FY2025
No daily prices have been collected for this company.
| Line | FY2021locked | FY2022locked | FY202312/23 | FY202412/24 | FY202512/25 |
|---|---|---|---|---|---|
| Operating profit | |||||
| Net finance cost | |||||
| Profit before tax | |||||
| Tax charge | |||||
| Profit for the year | |||||
| EBITDA | — | ||||
| Basic EPS | |||||
| Diluted EPS |
GBP millions, negatives in brackets. Per-share lines in pence. later is what a following report restated the figure to; vs is a second reading that disagrees. The figure shown is the one the original filing printed, and both readings are kept. Click any figure: opens the report page it was read from, highlighted; shows how it was calculated.
3 years, at a glance
C001020-AR-2025-ch